斯瑞新材(688102.SH):公司研發和生產的CT和DR球管零組件,應用於亟需國產化替代的高端醫療影像領域
格隆匯6月15日丨有投資者向斯瑞新材(688102.SH)提問,“公司醫療領域CT球管和DR球管零組是否做到了國產替代?”
斯瑞新材回覆稱,公司致力於解決國家關鍵基礎材料的進口替代和“卡脖子”問題,打造了高性能金屬材料設計、生產設備設計和生產工藝設計的綜合能力,形成從材料製備到下游零組件產品精密加工的一體化生產體系。公司研發和生產的CT和DR球管零組件,應用於亟需國產化替代的高端醫療影像領域,已經實現對聯影醫療、西門子、崑山醫源、無錫麥默、中國電子科技集團第十二研究所、珠海瑞能等國產設備及球管主要生產企業的供貨,通過進口替代逐步成為我國CT球管和DR球管零組件的國內主要供應商。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.